As a result, recruitment of Cas3 by the Csy complex is inhibited, thus effectively preventing the degradation of phage DNA by the CRISPR/Cas system. Cas3 plays critical roles during the process of ...
One is Locus Biosciences, which is utilising a CRISPR-Cas3 system to create its treatments. A spokesperson for the company explained to pharmaphorum the reason behind this: “Cas3’s ability to ...
Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...
9 After characterizing CRISPR’s role as a defense mechanism in bacteria, researchers soon realized that they could harness this system for gene manipulation in any cell. All they needed to do was ...
SNIPR BIOME ApS (“SNIPR” or “the Company”), a clinical stage biotech company pioneering CRISPR-based therapies, today announces grant of patent EP4392563B on February 24th 2025 by the European Patent ...
A team of researchers from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has developed a point-of-care testing (POCT) system based on microfluidic CRISPR-Dx technology, ...
This system and its uses do not rely on Cas9 or Cas3. The patent covers use of the ... for editing prokaryotes and eukaryotes using CRISPR-Cas. SNIPR's patent filings were the first in the field ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback